Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

Effects of the presence of stabilimentum concerning prey vibration acting in the direction tangent to the spiral threads. by G. Greco (7636232)

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Key significant pathways in the final models of self-compassion. by Eriko Takahashi (22608061)

Subjects:

Univariable and multivariable analyses (age-adjusted), concerning a selection of medicaments p < 0.1 and n ≥ 10. by P.G.J. ter Horst (21743830)

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning medicament(s) use and Low Semen Quality (LSQ). by P.G.J. ter Horst (21743830)

Decreased expression of tight junction proteins and disruption of intestinal barrier integrity in DSS-induced colitis mouse model. by Mariam Wed Eladham (21439745)

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

Subjects:

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning a selection of medicaments with n ≥ 10 medicament users and p < 0.1 by univariate analysis.... by P.G.J. ter Horst (21743830)

Distribution of responses to vital signs. by Lisa Thiele (6468056)

“…Increasing knowledge may enhance patient and family confidence to identify deterioration and escalate concerns. However, barriers to consumer escalation decrease this potential. …”

Survey tool development process. by Lisa Thiele (6468056)

“…Increasing knowledge may enhance patient and family confidence to identify deterioration and escalate concerns. However, barriers to consumer escalation decrease this potential. …”

Respondent characteristics. by Lisa Thiele (6468056)

“…Increasing knowledge may enhance patient and family confidence to identify deterioration and escalate concerns. However, barriers to consumer escalation decrease this potential. …”